Loading...
Nuclear Medicine Billing Services
A nuclear medicine claim is usually three or more lines: the study (78xxx), the radiopharmaceutical (A95xx or A96xx), and for cardiac studies the stress test and stress agent. Each line has its own coverage rule and component split. Qualigenix codes the study, the tracer, and the components together, checks PET coverage against Medicare's national coverage determinations before the scan, and ties radiopharmaceutical charges to the dose record.
Nuclear Medicine Billing Services
A nuclear medicine claim is usually three or more lines: the study (78xxx), the radiopharmaceutical (A95xx or A96xx), and for cardiac studies the stress test and stress agent. Each line has its own coverage rule and component split. Qualigenix codes the study, the tracer, and the components together, checks PET coverage against Medicare's national coverage determinations before the scan, and ties radiopharmaceutical charges to the dose record.
01
Study Extent and Method Coding
Nuclear medicine codes depend on the imaging method and the anatomic extent. PET/CT for tumor imaging is coded by area (78814–78816), SPECT/CT by area and number of days (78830–78832), and myocardial perfusion by single or multiple studies (78451–78454). Coding the wrong extent or method is a frequent cause of nuclear medicine underpayment and denial.
02
PET and Theranostics Prior Auth
Commercial and Medicare Advantage plans often send PET/CT and nuclear cardiology to a radiology benefit manager for approval. Radioligand therapies such as Lutetium-177 dotatate and Lutetium-177 vipivotide tetraxetan are high-cost drugs that most plans approve case by case.
03
Radiopharmaceutical Units
Each radiopharmaceutical has its own HCPCS code and billing unit: some per study dose, some per millicurie, and radium-223 per microcurie. Units have to match the dose administered. In hospital outpatient departments, most diagnostic radiopharmaceuticals are packaged into the study payment, though CMS began paying separately in 2025 for those above a per-day cost threshold.
04
TC/26 Component Splits
In a hospital, the facility bills the technical component and the nuclear medicine physician or cardiologist bills the professional component with modifier 26. In an office or independent diagnostic testing facility, the global service may be billed together. If the component and the site don't match, the claim is denied or paid twice and later recouped.
05
PET Coverage Rules
Medicare covers PET under the NCD 220.6 series, with FDG PET for cancer under NCD 220.6.17, and the indication on the claim has to match a covered use. Commercial payers publish their own imaging policies, and some limit how often PET can be repeated during treatment.
06
Orders and Supervision
Medicare requires a diagnostic test to be ordered by the treating physician or practitioner (42 CFR 410.32) and performed under the supervision level CMS assigns to that code. The diagnosis on the order has to support the study billed.
07
Recurring Denials
The recurring nuclear medicine denials are stress test components (93015–93018) billed in conflict with the perfusion study or by the wrong party, missing or unsigned orders, and diagnosis codes that don't meet the payer's medical-necessity list for the study.
08
NRC Authorized-User Rules
Radiopharmaceutical therapy is given by or under an authorized user licensed under NRC rules (10 CFR Part 35) or Agreement State rules. The physician named on the claim should match the authorized user and the supervision documented for the administration.
How Qualigenix Closes Nuclear Medicine Revenue Gaps
Qualigenix closes nuclear medicine revenue gaps by coding the study, tracer, and components as one claim and checking coverage before the patient is scanned.
Study-Level Coding
Coders read the final report for method, extent, and add-on work, then sequence stress test and agent codes so they pass NCCI edits.
Imaging Auth Management
We submit benefit-manager authorizations with the clinical criteria each payer requires and track theranostics approvals by cycle.
Dose-Matched Tracer Billing
We reconcile every radiopharmaceutical line to the administered dose and billing unit before the claim goes out. Across our client base, the charge-entry error rate is 1.6%.
Component Billing by Site
We assign technical, professional, or global billing by setting and confirm which party bills each component under your facility agreements.
Pre-Scan Coverage Checks
We check each PET indication against the Medicare NCD or the payer's imaging policy before scheduling, and use an ABN where Medicare coverage is uncertain.
Order and Supervision Review
We confirm a signed order from the treating practitioner and the required supervision documentation for every study.
Denial Recovery
Our denial team overturns 79% of the denials it works, with an average appeal turnaround under 9 days. Appeals cite the NCD, the payer policy, or the NCCI edit behind the claim.
Compliance Monitoring
We audit order, supervision, and authorized-user documentation on nuclear medicine claims each month.
CASE STUDY 01
How a 3-provider podiatry group cleared $214K in aged A/R
THE SITUATION
A 3-provider podiatry group with roughly 60% Medicare payer mix carried $412,000 in A/R, 38% of it past 120 days. Routine foot care claims (11720, 11721, 11055–11057) had stalled on inconsistent Q7/Q8/Q9 modifiers and class-finding documentation, so payers held or partially paid and nobody worked the remainder. Medicare crossover to secondaries was not being posted, and small patient balances were written off.
WHAT QUALIGENIX DID
We ran a full A/R aging segmentation, worked claims by payer and denial reason rather than by date, rebilled the stalled routine-care claims with corrected modifiers, and reactivated secondary and crossover billing.
Key Outcomes & Turnaround
38% to 14%A/R past 120 days
$214,000recovered from aged A/R
90 daysto turn it around
~60%Medicare payer mix
Audited Practice Results
How a solo podiatrist lifted first-pass acceptance to 96%
THE SITUATION
A solo podiatrist coding 320 encounters a month was stuck at 82% first-pass acceptance. Routine foot care went out without the systemic-condition diagnosis pairing and class findings Medicare requires, so it read as non-covered. Wound debridement was coded to the wrong depth (11042 for skin and subcutaneous where the note supported 11043 for muscle and fascia). Same-day E/M with a procedure went out without modifier 25 and got bundled.
WHAT QUALIGENIX DID
We rebuilt the coding workflow: diagnosis-to-CPT pairing rules for at-risk foot care, correct Q-modifier logic, depth-based debridement coding tied to the operative note, and disciplined use of modifiers 25 and 59/XS.
Key Outcomes & Turnaround
82% to 96%first-pass acceptance
+11%per-encounter reimbursement
60 daysto turn it around
320/moencounters coded
Audited Practice Results
How a 2-location podiatry practice cut its denial rate by two-thirds
THE SITUATION
A 2-location podiatry practice sat at a 19% denial rate, mostly Medicare routine-foot-care and nail-debridement rejections. The denials clustered in three buckets: medical-necessity rejections on routine foot care (missing qualifying diagnosis and class findings), frequency-edit denials on nail debridement billed inside the 60-day window, and missing Q modifiers that flagged services as non-covered.
WHAT QUALIGENIX DID
We built a front-end denial-prevention layer, checking eligibility and coverage against payer LCDs before claims went out, plus a structured appeal workflow with documentation templates mapped to each denial reason.
Key Outcomes & Turnaround
19% to 6%denial rate
$68,000recovered on appealed claims
4 monthsto turn it around
2 locationspractice size
Audited Practice Results
Nuclear Medicine Coding by Study Type
Qualigenix codes nuclear medicine by study type, because each study family has its own tracer, component, and coverage rules.
PET and PET/CT
Codes: 78811–78816; A9552, A9595. PET and PET/CT by anatomic extent, with tracers such as F-18 FDG (A9552) and F-18 piflufolastat for PSMA PET (A9595).
The Nuclear Medicine Providers We Work With
Qualigenix works with nuclear medicine physicians, hospital imaging departments, PET/CT centers and independent diagnostic testing facilities, cardiology-affiliated nuclear labs, theranostics programs, and multi-site imaging networks.
0%
Audit Pass Rate
<0%
Variance Threshold
Why Qualigenix
0%
IMPROPER PAYMENT RATE
0%
FROM DOC GAPS
0%
FROM CODING ERRORS
$0M+
PAID IN ERROR
QUESTIONS BUYERS ASK
Qualigenix prices nuclear medicine billing after reviewing your study volume, settings, payer mix, and the services you want to hand over. Most labs start with a free billing audit so the quote reflects real numbers.
We bill each radiopharmaceutical with its own HCPCS code and in its defined unit, per study dose, per millicurie, or per microcurie, matched to the dose record for that patient.
We check each PET indication against Medicare's NCD 220.6 series before the scan and use an Advance Beneficiary Notice when coverage is uncertain.
Yes. We work existing nuclear medicine and imaging claims by denial reason and timely-filing limit, starting with the highest-value accounts. A free AR review shows how much is still recoverable.
We submit authorizations to each payer or radiology benefit manager with the clinical criteria it requires, and we track approval status before the scan date. A free audit shows where your current auth denials start.
Yes. We bill global, technical-only (TC), or professional-only (modifier 26) claims based on the site of service and who owns the equipment.
Qualigenix works across 133 EMR/EHR platforms, including radiology information systems. We confirm access to your RIS and EHR during the free billing audit.
Qualigenix's average onboarding time is 6 days. That covers system access, payer enrollment checks, and coder assignment before we take over claim submission.